Latest news with #ShrikantAkolkar
&w=3840&q=100)
Business Standard
2 days ago
- Business
- Business Standard
Sun Pharma launches Leqselvi in US after patent settlement with Incyte Corp
Sun Pharmaceuticals on Monday announced the launch of hair loss drug Leqselvi (deuruxolitinib) in the United States (US) market for the treatment of alopecia areata, a condition in which the immune system attacks hair follicles, leading to hair loss on the scalp as well as other parts of the body. The announcement came after the Mumbai-based pharma major inked a settlement pact with US-based Incyte Corporation regarding the hair loss drug. Incyte had earlier accused Sun Pharma of patent infringement. Under the terms of the agreement, the parties will seek dismissal of the pending Leqselvi litigation in the United States District Court for the District of New Jersey. 'Incyte has also granted Sun a limited and non-exclusive licence to US patent numbers 9,662,335 and certain other related patents with respect to oral deuruxolitinib for certain agreed-upon non-haematology-oncology indications including alopecia areata, in the US,' the company said in a regulatory filing on the exchanges. The Mumbai-based pharma major will also pay Incyte an undisclosed upfront amount, plus ongoing royalty payments until the expiry of the patents, in exchange for the settlement and licence. Deuruxolitinib is expected to go off-patent in the financial year 2025–26 (FY26). The launch adds Leqselvi to Sun Pharma's innovative therapies portfolio, which saw sales of $1,216 million in FY25, according to Sun Pharma's investor presentation for the year. According to a Reuters report, Shrikant Akolkar, analyst at Nuvama Institutional Equities, said the drug could generate up to $400 million in sales by FY30, with peak sales potential of $900 million, and boost growth in Sun Pharma's key US market. Commenting on the launch, Sun Pharma America CEO Richard Ascroft said the launch of Leqselvi in the US brings an effective, new treatment option for severe alopecia areata to eligible patients and the healthcare providers who treat them. 'As a company committed to launching new therapeutic options which address the unmet needs of patients, adding Leqselvi to our dermatology portfolio represents a key milestone for the business and an important advancement for the alopecia areata community,' he added. The announcement was made post market hours. On Monday, Sun Pharma's share rose marginally by 0.57 per cent, ending the day's trade at ₹1,682.05 apiece on the Bombay Stock Exchange (BSE).
&w=3840&q=100)
Business Standard
2 days ago
- Business
- Business Standard
Sun Pharma launches hair loss drug Leqselvi in US after patent settlement
The delay in Sun Pharma's launch of Leqselvi in the US was caused by a patent infringement case, which was later settled in a US court with Incyte Corp New Delhi Sun Pharmaceutical has launched a new medicine for severe alopecia areata, called Leqselvi, in the United States. Alopecia areata is a condition in which the immune system attacks hair follicles, leading to hair loss on the scalp as well as other parts of the body. 'Leqselvi is an important step forward for people living with severe alopecia areata,' said Richard Ascroft, CEO of Sun Pharma North America. 8 mg Leqselvi tablets for severe alopecia areata is now available by prescription across the US. The delay in Sun Pharma's launch of Leqselvi in the US was caused by a patent infringement case, which was later settled in a US court with Incyte Corp, as reported by Reuters. The drug underwent two clinical trials, THRIVE-AA1 and THRIVE-AA2, involving 1,223 adults between 18 and 65 years of age. The trials were conducted in the US, Canada, and Europe. Hair regrowth was measured over a period of 24 weeks using a scoring system known as the Severity of Alopecia Tool (SALT), according to the company's statement. Shrikant Akolkar, analyst at Nuvama Institutional Equities, said the drug could generate up to $400 million in sales by FY30, with peak sales potential of $900 million, and boost growth in Sun's key US market, according to Reuters. The National Alopecia Areata Foundation (NAAF) welcomed the launch. Its President, Nicole Friedland, said the new treatment offers hope to many people dealing with the emotional and social impacts of hair loss. Sun Pharmaceutical is also offering a 'Leqselvi Support Program' to help patients access the medicine. Eligible patients may be able to receive the drug for as little as $0 for up to two years. The program also includes personal guidance and support throughout the treatment process. 'The clinical evidence for Leqselvi is truly compelling, demonstrating consistent efficacy," said Arash Mostaghimi, Vice Chair of Clinical Trials and Innovation and Associate Professor of Dermatology at Brigham and Women's Hospital. However, Leqselvi does carry certain risks. It may cause side effects such as infections, acne, headaches, or more serious health issues. Doctors are advised to screen patients thoroughly before and during treatment. Alopecia areata affects nearly 2.5 per cent of people in the United States during their lifetime. According to figures cited in the company's release, the condition also affects a similar percentage of the global population. The scalp is the most commonly affected area, but hair loss can also occur on other parts of the body.
Yahoo
2 days ago
- Business
- Yahoo
India's Sun Pharma launches hair loss drug Leqselvi in US after patent settlement
By Rishika Sadam (Reuters) -India's top drugmaker by revenue Sun Pharma on Monday launched its anti-baldness drug Leqselvi in the U.S., following the settlement of a patent dispute with Incyte Corp. The company said 8 mg Leqselvi tablets for severe alopecia areata will be available in the U.S., after a launch delay caused by a patent infringement case in a U.S. court. Shrikant Akolkar, analyst at Nuvama Institutional Equities, said the drug could generate up to $400 million in sales by FY30, with peak sales potential of $900 million, and boost growth in Sun's key U.S. market. "This settlement is very positive and there is no overhang of any legal dispute anymore. The drug has very good clinical data and with this launch, Sun Pharma's commercial portfolio broadens further," he said. India's drugmakers have been grappling with pricing pressure and stiff competition in the U.S. The company said the drug's addition to its dermatology portfolio is a "key milestone", as it focuses on new therapy areas. Alopecia areata is an autoimmune disease that causes patchy hair loss on the scalp and other areas of the body. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
28-06-2025
- Business
- Business Insider
Nuvama Remains a Buy on Aurobindo Pharma Ltd (AUROPHARMA)
In a report released yesterday, Shrikant Akolkar from Nuvama maintained a Buy rating on Aurobindo Pharma Ltd (AUROPHARMA – Research Report), with a price target of INR1,460.00. The company's shares closed yesterday at INR1,121.00. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Akolkar is a 2-star analyst with an average return of -2.3% and a 0.00% success rate. Akolkar covers the Healthcare sector, focusing on stocks such as Aurobindo Pharma Ltd, Cipla Ltd, and Jubilant Pharmova Limited. Currently, the analyst consensus on Aurobindo Pharma Ltd is a Moderate Buy with an average price target of INR1,430.00. Based on Aurobindo Pharma Ltd's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of INR83.82 billion and a net profit of INR9.03 billion. In comparison, last year the company earned a revenue of INR75.8 billion and had a net profit of INR9.09 billion
Business Insider
28-06-2025
- Business
- Business Insider
Nuvama Sticks to Their Buy Rating for Jubilant Pharmova Limited (JUBLPHARMA)
In a report released yesterday, Shrikant Akolkar from Nuvama maintained a Buy rating on Jubilant Pharmova Limited (JUBLPHARMA – Research Report), with a price target of INR1,385.00. The company's shares closed yesterday at INR1,173.90. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Akolkar is a 2-star analyst with an average return of -2.3% and a 0.00% success rate. Akolkar covers the Healthcare sector, focusing on stocks such as Aurobindo Pharma Ltd, Cipla Ltd, and Jubilant Pharmova Limited. The word on The Street in general, suggests a Hold analyst consensus rating for Jubilant Pharmova Limited. Based on Jubilant Pharmova Limited's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of INR19.29 billion and a net profit of INR1.54 billion. In comparison, last year the company earned a revenue of INR17.59 billion and had a GAAP net loss of INR586 million
